Cellebrite (CLBT) Q2 2026 Earnings Call Transcript
Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.
How this was made
The 30-second read
Why it matters
The guidance downgrade signals lower revenue growth, but new contracts and product adoption could provide upside later in the year.
Market read
Guidance cut is material for investors; the CEO transition adds strategic uncertainty.
What to watch
Large FedRAMP deal and 25% growth in defense ARR may offset short‑term revenue shortfall.
Background
Cellebrite, a provider of digital forensics tools to government agencies, reported weaker-than-expected Q2 performance and revised its full‑year outlook.
Ticker impact
Cellebrite announced a new CEO and lowered its full-year ARR and revenue outlook during its Q2 2026 earnings call.
Potential short-term downside as investors adjust expectations.
Guidance revisions are primary new information that directly affect valuation.
Market effects
May weigh on digital forensics and security software peers.
U.S. and European government contract outlook could be reassessed.
Limited to firms serving public‑sector customers.
Counterpoint
If the new CEO accelerates product rollout, the guidance cut could be temporary.
Key entities
- ExecutiveShiv Ramji
Newly appointed CEO of Cellebrite.
- ExecutiveTom Hogan
Outgoing CEO and former Executive Chairman.
